Cor Vasa 2014, 56(3):e246-e253 | DOI: 10.1016/j.crvasa.2014.04.005

Dual antiplatelet therapy in patients with acute coronary syndrome treated by surgical revascularization

Jiří Pařenica^a,b,c,*, Petr Němec^c,d

^a Interní kardiologická klinika, Fakultní nemocnice Brno, Brno, Česká republika

^b Lékařská fakulta Masarykovy univerzity, Brno, Česká republika

^c Mezinárodní centrum klinického výzkumu, Fakultní nemocnice u sv. Anny v Brně, Brno, Česká republika

^d Centrum kardiovaskulární a transplantační chirurgie, Brno, Česká republika

Twelve-month dual antiplatelet therapy (DAPT) based on a combination of acetylsalicylic acid and purine receptor P2Y12 inhibitor is a standard for all patients with acute coronary syndrome (unstable angina pectoris, NSTEMI and STEMI). Previous sub-analysis of CURE and ACUITY studies suggested that DAPT could bring benefit even for patients treated by surgical revascularization. Sub-analysis of PLATO trial conducted on 1261 patients who underwent surgical revascularization within 12 months demonstrated a reduction of cardiovascular and total mortality within a group of patients treated with ticagrelor and acetylsalicylic acid compared to patients treated with clopidogrel and acetylsalicylic acid.

Keywords: Acute coronary syndrome; CABG; Clopidogrel; Dual antiplatelet therapy; Surgery revascularization; Ticagrelor

Received: January 18, 2014; Revised: April 26, 2014; Accepted: April 29, 2014; Published: June 1, 2014  Show citation